Sorafenib effect on HCC survival depends on hepatitis status

January 9, 2017

(HealthDay)—For patients with advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival (OS) is dependent on patients' hepatitis status, according to a meta-analysis published online Jan. 3 in the Journal of Clinical Oncology.

Richard Jackson, from the Liverpool Cancer Trials Unit in the United Kingdom, and colleagues undertook an individual patient data meta-analysis of three prospective randomized trials in which sorafenib was the control arm. Data were included for 1,643 patients with advanced unresectable hepatocellular carcinoma who received sorafenib.

The researchers found that patients who were both hepatitis B virus (HBV) negative and hepatitis C virus (HCV) positive had improved OS for sorafenib (log [hazard ratio], −0.27). In this subgroup, the median unadjusted survival was 12.6 and 10.2 months for sorafenib and other treatments, respectively. Other patient subgroups defined by HBV and HCV did not have improvement in OS. Consistent results were seen across all trials.

"There is consistent evidence that the effect of sorafenib on OS is dependent on patients' hepatitis status," the authors write. "There is an improved OS for patients negative for HBV and positive for HCV when treated with ."

One author disclosed financial ties to the pharmaceutical industry; Bristol-Myers Squibb, Pfizer, and AbbVie gave access to data from studies in which they acted as sponsor.

Explore further: Sorafenib treatment alters immunosuppressive phenotypes in hepatocellular carcinoma

More information: Full Text (subscription or payment may be required)

Related Stories

Sorafenib, sunitinib may pose cardiovascular risk

October 13, 2015

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

Adjuvant chemo plus CRT best in nasopharyngeal carcinoma

December 19, 2016

(HealthDay)—For nonmetastatic nasopharyngeal carcinoma, the addition of adjuvant chemotherapy (AC) to chemoradiotherapy (CRT) is associated with the highest survival benefit, according to research published online Dec. ...

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.